The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells - Wikidata - wikimedia - TriplyDB

The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells

The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells

http://www.wikidata.org/entity/Q35744471

about

Update: the status of clinical trials with kinase inhibitors in thyroid cancer In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.Molecular pathogenesis and mechanisms of thyroid cancer Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer.Disruption of mutated BRAF signaling modulates thyroid cancer phenotype New therapies for dedifferentiated papillary thyroid cancer Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma Evolving approaches to patients with advanced differentiated thyroid cancer Biomarkers of response to Akt inhibitor MK-2206 in breast cancer MK-2206, an AKT inhibitor, promotes caspase-independent cell death and inhibits leiomyoma growth.Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma.Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells.Recent Advances on Small-Molecule Survivin Inhibitors.Genetics and epigenetics of sporadic thyroid cancer.Selective use of vandetanib in the treatment of thyroid cancer.PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro.Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines.Thyroid cancer cell lines: Critical models to study thyroid cancer biology and new therapeutic targets.PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells.Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells.MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.

P2860

Q33570056-90776636-85CA-455E-9B1B-EA8D41107181 Q33601377-597A3BB5-F075-4FB4-B1A3-074141A99B8D Q34329018-C69ADFB0-03FE-4ADE-9E3A-8577C4A6852F Q35104869-C2DDFE9C-EA08-4F8C-B6BF-818DFD9A175E Q35132767-4FEA3F81-4D1F-489A-8BEE-44FA974BC934 Q35381593-46332F7B-D754-4148-AF81-C9D2D465526E Q36634818-64809416-691B-471D-8102-6A5E0DCE7D47 Q36799818-523F1064-2201-46B1-AD6E-5B25128E675A Q36864736-406C492F-927C-4AD9-95EC-0C51031D22BA Q37168778-A02FCC10-B1D4-422C-A140-7CF30394AA36 Q37240206-D79532D0-8113-499F-BA64-D9B4D924AED1 Q37625891-2391D3F9-38F1-4F7A-8F09-01289EBD2180 Q37635839-2FF54128-8111-4EED-ADB9-6F3F56EEDF53 Q37689286-C32E6B11-08FC-40BC-B91C-A195198F3AA7 Q38128097-769CDA0C-7779-4DE9-B6DE-D0FE323E6964 Q38546474-0F4885F9-68BC-43EB-8D87-666E2CF32658 Q38644584-49B10068-18D9-40D0-A9FD-6C52B28D5A32 Q39245623-5B76CFC5-32C3-4D37-AE0D-57CB521AC2B2 Q39246432-C95F2D17-71A5-4C8D-BD3F-F7418C192894 Q39326839-6AFDDBD8-A78D-4B2B-8EF5-31445DB47167 Q41628138-40391DC1-FE5E-4867-9502-3D31E455B108 Q42370484-F2519F1E-17BA-4268-A417-9B98D1597E82 Q48273491-9435E50C-1CF7-400F-ABA7-7B70EC09289D Q54111658-D39F7C95-C93F-401F-B359-63EE46AFC1F2

P2860

The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells

http://www.wikidata.org/entity/Q35744471

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

The Akt inhibitor MK2206 syner ...... bition of thyroid cancer cells

@ast

The Akt inhibitor MK2206 syner ...... bition of thyroid cancer cells

@en

type

label

The Akt inhibitor MK2206 syner ...... bition of thyroid cancer cells

@ast

The Akt inhibitor MK2206 syner ...... bition of thyroid cancer cells

@en

prefLabel

The Akt inhibitor MK2206 syner ...... bition of thyroid cancer cells

@ast

The Akt inhibitor MK2206 syner ...... bition of thyroid cancer cells

@en

P1433

Q35744471-ACC8FA3C-A689-4F1C-8D76-CD1ED872A490

P1476

Q35744471-8DD19A24-EC93-4F47-878D-33986BAC8D55

P2093

Q35744471-6A31ED6B-5995-43D7-B7F9-DDCD73A9A63E

Q35744471-9F962854-F8DB-440F-A06B-9E94A40DA700

P2860

Q35744471-041CDFA0-CA09-4FD1-B920-631CEE0E7F15

Q35744471-04552E15-59A5-4A20-95B1-D7A0856FA112

Q35744471-04738C30-35A9-4FD7-8824-D54A4164C3CD

Q35744471-118050D7-7CBC-43DA-98FD-9AB809E1ACBB

Q35744471-15AFF7E0-FE0F-4442-BF90-BD47867D6F73

Q35744471-24C1E64B-0C69-4E8B-93AB-1F6153EB4993

Q35744471-265CE274-81F0-4366-B3FC-A4353C40D125

Q35744471-379C7215-8599-4058-A301-CE285CC4AF6D

Q35744471-3A51D04C-A345-4FBC-A806-07CFE6FF41A8

Q35744471-3C3FDAB4-5F13-45E8-B921-F94D0B39B007

P304

Q35744471-84147800-299B-4609-B89D-7F950FA4EB6F

P31

Q35744471-27DAFDFF-4906-4294-828B-8C6541D4760B

P356

Q35744471-F4693567-0F35-449C-BF67-CE7DDBC73765

P407

Q35744471-AE6C8BC6-6EB0-4015-A26C-C08C6A660BF8

P433

Q35744471-6F1852BD-88E2-41F9-980F-A9F167ED1292

P478

Q35744471-E6D67800-821C-4D20-9589-5D89A3FE35AE

P50

Q35744471-1995EC3C-B7C3-423A-B242-845FB68953DC

P577

Q35744471-9F4C0D6C-BA78-4C48-B025-DEB691DC96B4

P698

Q35744471-CB7C5079-682D-4895-8841-DE61194978CB

P932

Q35744471-F478E888-02BC-4B3D-B71D-109E0237FEC3

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

The Akt inhibitor MK2206 syner ...... bition of thyroid cancer cells

@en

P2093

Mingzhao Xing

http://www.w3.org/2001/XMLSchema#string

Ruixin Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo

Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation

Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.

Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications.

Multiple functions of p27(Kip1) and its alterations in tumor cells: a review.

The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.

P304

E173-82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2011-1054

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22090271

http://www.w3.org/2001/XMLSchema#string

P932

3275354

http://www.w3.org/2001/XMLSchema#string